Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations
Completed · Phase 1
Conditions studied: Progranulin Mutation Carriers
In brief
The purpose of this study is to determine the maximum tolerated dose of nimodipine as well as the safety and tolerability of oral nimodipine in progranulin mutation carriers in preparation for longer term efficacy studies in patients with frontotemporal dementia due to progranulin gene mutations.
Key facts
- Study ID
- NCT01835665
- Run by
- University of California, San Francisco
- People needed
- 8
- Starts
- 2013-03-01
- Expected to finish
- 2016-05-01
- Last updated by the study team
- 2016-05-16
Who can join
Age: 30 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCSF Memory and Aging Center — San Francisco, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.